# China NMPA Drug Inspection - Guilin Pharmaceutical Co., Ltd. - Fritillaria and Loquat Syrup

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guilin-pharmaceutical-co-ltd/4536957e-80f5-4b17-bd23-83f1388e79c7/
Source feed: China

> China NMPA drug inspection for Guilin Pharmaceutical Co., Ltd. published January 26, 2018. Drug: Fritillaria and Loquat Syrup. On January 26, 2018, the Henan Provincial Food and Drug Administration announced findings from inspections conducted by 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Henan Provincial Food and Drug Administration Regarding Four Batches of Substandard Drugs (Issue 1, 2018)
- Company Name: Guilin Pharmaceutical Co., Ltd.
- Publication Date: 2018-01-26
- Drug Name: Fritillaria and Loquat Syrup
- Inspection Finding: Content not up to standard
- Action Taken: The relevant food and drug regulatory authorities have been instructed to take necessary risk control measures such as sealing up, seizing, and suspending the sale of substandard drugs, and to investigate and punish the suppliers of the substandard drugs in accordance with the law.
- Summary: On January 26, 2018, the Henan Provincial Food and Drug Administration announced findings from inspections conducted by various provincial and city-level drug inspection institutes, identifying four batches of substandard drugs. This action falls under the regulatory oversight of the Henan Provincial Food and Drug Administration, operating within China's National Medical Products Administration (NMPA) framework. The identified issues involved multiple entities.

Henan Qingshan Pharmaceutical Co., Ltd. produced Dictamnus dasycarpus root bark that was non-compliant due to unqualified levels of magnesium and aluminum salts. Agarwood sourced from Zhengzhou First People's Hospital was found to be deficient in rosin acid. Chuanbei Pipa Syrup, labeled as produced by Guilin Gexianweng Pharmaceutical Co., Ltd., failed content specifications. Additionally, Sodium Chloride Injection from Hubei Xinghua Pharmaceutical Co., Ltd. contained visible foreign matter.

As a result, the Henan Provincial Food and Drug Administration has directed relevant regulatory bodies to implement immediate risk control measures, including the sealing, seizure, and suspension of sales for the affected drugs. Further investigations will be conducted, and legal penalties will be applied to the responsible suppliers to ensure regulatory compliance and public safety.

Company: https://www.globalkeysolutions.net/companies/guilin-pharmaceutical-co-ltd/8a53776f-b81a-417d-b1c5-ea1cd2d0b0a8/